Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase
- PMID: 15286701
- DOI: 10.1038/sj.onc.1207995
Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase
Abstract
The antitumor activity of the sesquiterpene lactone parthenolide, an active ingredient of medicinal plants, is believed to be due to the inhibition of DNA binding of transcription factors NF-kappaB and STAT-3, reduction in MAP kinase activity and the generation of reactive oxygen. In this report, we show that parthenolide activates c-Jun N-terminal kinase (JNK), which is independent of inhibition of NF-kappaB DNA binding and generation of reactive oxygen species. Parthenolide reversed resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Cancer cells treated with a combination of TRAIL and parthenolide underwent massive typical apoptosis and atypical apoptosis involving the loss of plasma membrane integrity. JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. Parthenolide induced phosphorylation of Bid and increased TRAIL-dependent cleavage of Bid without affecting caspase 8 activities. Cytochrome c but not Smac/DIABLO was released from the mitochondria in cells treated with parthenolide alone. Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP). Enhanced XIAP cleavage correlated with increased and prolonged caspase 3 activity and PARP cleavage, suggesting that the sensitization to TRAIL involves 'feed forward' activation of caspase 3. These results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistance of cancer cells to TRAIL, particularly those with elevated XIAP levels.
Similar articles
-
Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.Clin Cancer Res. 2004 Oct 1;10(19):6650-60. doi: 10.1158/1078-0432.CCR-04-0576. Clin Cancer Res. 2004. PMID: 15475455
-
Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells.Carcinogenesis. 2004 Nov;25(11):2191-9. doi: 10.1093/carcin/bgh234. Epub 2004 Jul 15. Carcinogenesis. 2004. PMID: 15256485
-
NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).Anticancer Res. 2000 Nov-Dec;20(6B):4243-55. Anticancer Res. 2000. PMID: 11205254
-
Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.Vitam Horm. 2004;67:453-83. doi: 10.1016/S0083-6729(04)67023-3. Vitam Horm. 2004. PMID: 15110190 Review.
-
Mechanisms of resistance to TRAIL-induced apoptosis in cancer.Cancer Gene Ther. 2005 Mar;12(3):228-37. doi: 10.1038/sj.cgt.7700792. Cancer Gene Ther. 2005. PMID: 15550937 Review.
Cited by
-
Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.Oncotarget. 2015 May 20;6(14):12682-96. doi: 10.18632/oncotarget.3707. Oncotarget. 2015. PMID: 25926557 Free PMC article.
-
Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer.Lab Invest. 2014 Sep;94(9):950-65. doi: 10.1038/labinvest.2014.89. Epub 2014 Jul 28. Lab Invest. 2014. PMID: 25068660
-
Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells.J Med Chem. 2015 Nov 25;58(22):8896-906. doi: 10.1021/acs.jmedchem.5b01187. Epub 2015 Nov 16. J Med Chem. 2015. PMID: 26540463 Free PMC article.
-
Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres.Cancer Biol Ther. 2013 Feb;14(2):135-45. doi: 10.4161/cbt.22952. Epub 2012 Nov 28. Cancer Biol Ther. 2013. PMID: 23192276 Free PMC article.
-
Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.Bioorg Med Chem. 2016 Sep 1;24(17):3876-3886. doi: 10.1016/j.bmc.2016.06.028. Epub 2016 Jun 16. Bioorg Med Chem. 2016. PMID: 27396927 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous